Sean Landrette
Overview
Explore the profile of Sean Landrette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Snyder L, Neklesa T, Willard R, Gordon D, Pizzano J, Vitale N, et al.
Mol Cancer Ther
. 2024 Dec;
PMID: 39670468
Androgen receptor (AR) signaling is the principal driver of prostate cancer, and drugs that target this pathway (e.g., abiraterone and enzalutamide) are standard treatments for metastatic hormone-sensitive prostate cancer and...
2.
Babu S, Nicholson K, Rothstein J, Swenson A, Sampognaro P, Pant P, et al.
Brain
. 2024 Apr;
147(9):2998-3008.
PMID: 38606777
Apilimod dimesylate is a first-in-class phosphoinositide kinase, FYVE-type zinc finger-containing (PIKfyve) inhibitor with a favourable clinical safety profile and has demonstrated activity in preclinical C9orf72 and TDP-43 amyotrophic lateral sclerosis...
3.
Beeharry N, Landrette S, Gayle S, Hernandez M, Grotzke J, Young P, et al.
Blood Adv
. 2019 Nov;
3(22):3661-3673.
PMID: 31751472
Acute myeloid leukemias (AML) harboring a constitutively active internal tandem duplication (ITD) mutation in the FMS-like kinase tyrosine kinase (FLT3) receptor are associated with poor patient prognosis. Despite initial clinical...
4.
Chang H, Pan Y, Landrette S, Ding S, Yang D, Liu L, et al.
Proc Natl Acad Sci U S A
. 2019 Aug;
116(37):18507-18516.
PMID: 31451639
Genome-wide phenotypic screens provide an unbiased way to identify genes involved in particular biological traits, and have been widely used in lower model organisms. However, cost and time have limited...
5.
Gayle S, Landrette S, Beeharry N, Conrad C, Hernandez M, Beckett P, et al.
Autophagy
. 2017 Mar;
13(6):1082-1083.
PMID: 28350209
We identified the PIKFYVE inhibitor apilimod as a potent and selective cytotoxic agent against B-cell non-Hodgkin lymphoma (B-NHL). Our data robustly establish PIKFYVE as the target through which apilimod kills...
6.
Gayle S, Landrette S, Beeharry N, Conrad C, Hernandez M, Beckett P, et al.
Blood
. 2017 Jan;
129(13):1768-1778.
PMID: 28104689
We identified apilimod as an antiproliferative compound by high-throughput screening of clinical-stage drugs. Apilimod exhibits exquisite specificity for phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) lipid kinase and has selective cytotoxic activity in B-cell...
7.
Gayle S, Pan Y, Landrette S, Xu T
Stem Cell Reports
. 2015 Apr;
4(5):926-38.
PMID: 25866159
The mechanisms regulating human embryonic stem (ES) cell self-renewal and differentiation are not well defined in part due to the lack of tools for forward genetic analysis. We present a...